MedPath

Modulation of Visually Evoked Potentials by an Antidepressant

Not Applicable
Completed
Conditions
Depression
Registration Number
NCT00263133
Lead Sponsor
University Hospital Freiburg
Brief Summary

12 normal healthy controls will be treated with 50 mg sertraline once daily for three weeks. Early amplitudes of visually evoked potentials will be examined at day 0, 10 and 21 and statistically compared. This study aims to examine a putative modulation of synaptic transmission and plasticity by an antidepressant and is part of a series of studies in healthy individuals and depressed patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • healthy individuals 18-65 years
Exclusion Criteria
  • history of affective oder other psyhiatric disorder
  • severe medical condition
  • pregnancy or ineffective contraception
  • active illicit drug use

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Amplitudes and latencies of early visually evoked potentials.
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Dept. of Psychiatry, University of Freiburg

🇩🇪

Freiburg, Germany

© Copyright 2025. All Rights Reserved by MedPath